<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04899505</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2021-02</org_study_id>
    <nct_id>NCT04899505</nct_id>
  </id_info>
  <brief_title>Evaluation of the Impact of Chemotherapy on Body Odor in Adolescents and Young Adults in Oncology</brief_title>
  <acronym>ODORAJA</acronym>
  <official_title>ODORAJA:Evaluation of the Impact of Chemotherapy on Body Odor in Adolescents and Young Adults in Oncology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The appearance of unpleasant body odors in adolescent Young adult (aya) wille be evaluated&#xD;
      undergoing chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2021</start_date>
  <completion_date type="Anticipated">December 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 21, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of the development of unpleasant body odors in AYA oncology patients</measure>
    <time_frame>8 months</time_frame>
    <description>Percentage of patients reporting discomfort with unpleasant body odor that occurred during their treatment. This percentage will be calculated from the response to item Q1 of the patient questionnaire during the fourth course of chemotherapy in the AJA oncology department</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Qualification of the smell and the discomfort felt</measure>
    <time_frame>8 months</time_frame>
    <description>Answers to the investigation intended for patients for the appearance of the smell with different proposals like sweating, urine, breath etc. (Q2), its qualifier with different proposals like desagreable, infective, nauseating, etc…(Q3) and the discomfort observed for themselves or for those around them (Q8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of the discomfort and the impact on quality of life</measure>
    <time_frame>8 months</time_frame>
    <description>Answers to the investigation intended for patients to assess the intensity of the smell with a scale (0= no smell and 10 = strong smell) (Q4), its daily impact with a scale (0=no impact and 10= high impact) (Q7) and solutions that can reduce smell with different proposals like perfume, cream, essential oil (Q9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify possible causes of the appearance of these new body odors</measure>
    <time_frame>8 months</time_frame>
    <description>Answers to the investigation for patients to assess the link between smell and drug treatment with different proposals like treatment, hospital's food or hospital cleaning product (Q5 and Q6)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <condition>Solid Tumor, Childhood</condition>
  <condition>Chemotherapy Effect</condition>
  <arm_group>
    <arm_group_label>Evaluation on appearance of unpleasant body odors</arm_group_label>
    <description>Incidence of the development of unpleasant body odors in AYA oncology patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation on appearance of unpleasant body odors</intervention_name>
    <description>Percentage of patients reporting discomfort with unpleasant body odor that occurred during their treatment. This percentage will be calculated from the response to item Q1 of the patient questionnaire during the fourth course of chemotherapy in the AJA oncology department.</description>
    <arm_group_label>Evaluation on appearance of unpleasant body odors</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients aged between 15 and 25 years with solid tumors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged between 15 and 25 years;&#xD;
&#xD;
          -  New patients treated at the Curie Institute and hospitalized in the AJA oncology&#xD;
             department;&#xD;
&#xD;
          -  Patient undergoing chemotherapy administered intravenously;&#xD;
&#xD;
          -  Solid tumors.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient undergoing oral chemotherapy;&#xD;
&#xD;
          -  Persons deprived of their liberty or under guardianship (including guardianship);&#xD;
&#xD;
          -  Inability to undergo medical monitoring of the trial for geographical, social or&#xD;
             psychological reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aurélie Thuleau</last_name>
    <phone>+33 1 44324228</phone>
    <email>drci.promotion@curie.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lobna Saidi</last_name>
    <phone>+33 1 72389334</phone>
    <email>lobna.saidi@curie.Fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie Thuleau</last_name>
      <phone>+33 1 44324228</phone>
      <email>drci.promotion@curie.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

